(Q34563261)

3 August 2017

title

Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma (English)

1 reference

3 August 2017

1 reference

1 reference

1 reference

8

Henry C Pitot

1 reference

3 August 2017

7

Judith S Kaur

1 reference

3 August 2017

3

James N Ingle

1 reference

3 August 2017

5

Lisa A Kottschade

1 reference

3 August 2017

Ravi D Rao

1

1 reference

3 August 2017

Shernan G Holtan

2

1 reference

3 August 2017

Gary A Croghan

4

1 reference

3 August 2017

Edward T Creagan

6

1 reference

3 August 2017

Svetomir N Markovic

9

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

3 August 2017

1 reference

3 August 2017

volume

106

1 reference

3 August 2017

issue

2

1 reference

3 August 2017

page(s)

375-382

1 reference

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

21 January 2018

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

Vinorelbine in combination with interleukin-2 as second-line treatment in patients with metastatic melanoma. A phase II study of the Hellenic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

Conventional dose melphalan is inactive in metastatic melanoma: results of an Eastern Cooperative Oncology Group Study (E1687).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

A phase II study of carboplatin, cisplatin, interferon-alpha, and tamoxifen for patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

Results of a randomized study comparing DTIC with TIC mustard in malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

Sequences of taxol and cisplatin: a phase I and pharmacologic study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

Phase II study of paclitaxel and carboplatin for malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

Phase II trial of carboplatin in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

Phase II trial of carboplatin in patients with metastatic malignant melanoma. A report from the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

A phase II trial of taxol in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

A phase II study of taxol in patients with malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

Paclitaxel plus carboplatin: an effective combination chemotherapy for advanced non-small-cell lung cancer or just another Elvis sighting?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

Supra-additive effect with concurrent paclitaxel and cisplatin in vulvar squamous cell carcinoma in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

A phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

Results of a phase II study of weekly paclitaxel plus carboplatin in patients with extensive small-cell lung cancer with Eastern Cooperative Oncology Group Performance Status of 2, or age > or = 70 years.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

Weekly carboplatin and paclitaxel in elderly non-small-cell lung cancer patients (>or=65 years of age): a phase II North Central Cancer Treatment Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21611

7 January 2021

Identifiers

DOI

10.1002/CNCR.21611

1 reference

3 August 2017

1 reference